Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

(2012) Charles Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Indications for single-dose activated charcoal administration in acute overdose

(2011) Geoffrey K. Isbister et al.   Current Opinion in Critical Care

Apixaban in Patients with Atrial Fibrillation

(2011) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy

(2011) Ammar Majeed et al.   THROMBOSIS RESEARCH

Recombinant Factor VIIa to Manage Major Bleeding from Newer Parenteral Anticoagulants

(2010) Kellie A Vavra et al.   ANNALS OF PHARMACOTHERAPY

Tissue Distribution and Elimination of [14C]Apixaban in Rats

(2010) L. Wang et al.   DRUG METABOLISM AND DISPOSITION

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

(2010) Michael Rud Lassen et al.   LANCET

Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

(2010) Michael Rud Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans

(2009) D. Zhang et al.   DRUG METABOLISM AND DISPOSITION

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Recombinant factor VIIa for warfarin-associated intracranial bleeding

(2008) Can Ilyas et al.   JOURNAL OF CLINICAL ANESTHESIA

Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies

(2008) P. C. WONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study

(2008) et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS